TABLE 1.
Baseline and treatment characteristics in patients receiving LOT1
| Characteristic * | Completed FACT‐Leu and EQ‐5D‐3L at baseline N = 828 | Overall N = 889 |
|---|---|---|
| Age, median (range), years | 68 (22‐99) | 68 (22‐99) |
| Male sex, n (%) | 530 (64.0) | 566 (63.7) |
| Race, n (%) | ||
| White | 747 (90.2) | 798 (89.8) |
| African‐American | 53 (6.4) | 56 (6.3) |
| Asian | 1 (0.1) | 3 (0.3) |
| Other | 5 (0.6) | 6 (0.7) |
| Not reported | 22 (2.7) | 26 (2.9) |
| US geographic region, n (%) | ||
| South | 335 (40.5) | 352 (39.6) |
| Midwest | 256 (30.9) | 277 (31.2) |
| West | 128 (15.5) | 140 (15.7) |
| Northeast | 102 (12.3) | 112 (12.6) |
| Not reported | 7 (0.8) | 8 (0.9) |
| ECOG PS, n (%) | ||
| 0 | 329 (39.7) | 347 (39.0) |
| 1 | 272 (32.9) | 296 (33.3) |
| ≥2 | 43 (5.2) | 47 (5.3) |
| Not reported | 184 (22.2) | 199 (22.4) |
| CCI score | ||
| Median (range) | 2.0 (2.0‐10.0) | 2.0 (2.0‐10.0) |
| ≤2, n (%) | 475 (57.4) | 511 (57.5) |
| ≥3, n (%) | 353 (42.6) | 378 (42.5) |
| Duration between CLL diagnosis and Registry enrollment, median (range), years | 1.5 (0–32) | 1.5 (0–32) |
| Rai stage, n (%) | ||
| 0 | 154 (18.6) | 172 (19.3) |
| I | 177 (21.4) | 191 (21.5) |
| II | 101 (12.2) | 108 (12.1) |
| III | 103 (12.4) | 107 (12.0) |
| IV | 101 (12.2) | 107 (12.0) |
| Not reported | 192 (23.2) | 204 (22.9) |
| Constitutional symptoms, n (%) | ||
| Fatigue | 444 (53.6) | 480 (54.0) |
| Night sweats | 213 (25.7) | 226 (25.4) |
| Weight loss | 151 (18.2) | 157 (17.7) |
| Fever | 58 (7.0) | 60 (6.7) |
| Other | 102 (12.3) | 113 (12.7) |
| Not reported | 291 (35.1) | 309 (34.8) |
| Institution type, n (%) | ||
| Academic | 80 (9.7) | 86 (9.7) |
| Community | 733 (88.5) | 787 (88.5) |
| Government | 15 (1.8) | 16 (1.8) |
| Treatment at enrollment, n (%) | ||
| FCR | 233 (28.1) | 246 (27.7) |
| BR | 183 (22.1) | 199 (22.4) |
| R monotherapy | 96 (11.6) | 103 (11.6) |
| Other | 316 (38.2) | 341 (38.4) |
Abbreviations: BR, bendamustine and rituximab; CCI, Charlson Comorbidity Index; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; EQ‐5D‐3L, EuroQol 5‐dimension 3‐level questionnaire; FACT‐Leu, Functional Assessment of Cancer Therapy–Leukemia; FCR, fludarabine, cyclophosphamide, and rituximab; R, rituximab; LOT1, first‐line therapy.
*
Rounding may cause totals to be < or > 100%.